Dora Ding

774 total citations
10 papers, 287 citations indexed

About

Dora Ding is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Dora Ding has authored 10 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 7 papers in Hepatology and 3 papers in Oncology. Recurrent topics in Dora Ding's work include Liver Diseases and Immunity (7 papers), Liver Disease Diagnosis and Treatment (7 papers) and Liver Disease and Transplantation (3 papers). Dora Ding is often cited by papers focused on Liver Diseases and Immunity (7 papers), Liver Disease Diagnosis and Treatment (7 papers) and Liver Disease and Transplantation (3 papers). Dora Ding collaborates with scholars based in United States, United Kingdom and Spain. Dora Ding's co-authors include Robert P. Myers, Andrew J. Muir, Zachary Goodman, Catherine Jia, Nezam H. Afdhal, Ryan S. Huss, John G. McHutchison, Bertus Eksteen, Stephen H. Caldwell and Eric Lawitz and has published in prestigious journals such as Hepatology, Journal of Hepatology and Clinical Gastroenterology and Hepatology.

In The Last Decade

Dora Ding

9 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dora Ding United States 5 208 180 62 53 43 10 287
Philippe Kolly Switzerland 9 209 1.0× 189 1.1× 33 0.5× 47 0.9× 20 0.5× 10 306
Hiroaki Hashizume Japan 9 202 1.0× 147 0.8× 117 1.9× 59 1.1× 67 1.6× 15 307
Ashley M. Lakner United States 7 157 0.8× 151 0.8× 63 1.0× 138 2.6× 17 0.4× 8 322
Jui‐Ting Hu Taiwan 10 222 1.1× 178 1.0× 33 0.5× 54 1.0× 17 0.4× 24 340
Aurora Giannetti Italy 6 203 1.0× 102 0.6× 26 0.4× 24 0.5× 84 2.0× 13 262
Anna Ludovica Fracanzani Italy 6 169 0.8× 105 0.6× 35 0.6× 17 0.3× 50 1.2× 9 237
Stefanie Haegele Austria 9 140 0.7× 211 1.2× 136 2.2× 36 0.7× 7 0.2× 18 324
Takuya Nagano Japan 9 136 0.7× 160 0.9× 48 0.8× 25 0.5× 22 0.5× 25 262
Emily Zhang United States 4 209 1.0× 210 1.2× 22 0.4× 28 0.5× 17 0.4× 5 280
Yoshiou Ikeda Japan 10 141 0.7× 123 0.7× 101 1.6× 53 1.0× 10 0.2× 29 353

Countries citing papers authored by Dora Ding

Since Specialization
Citations

This map shows the geographic impact of Dora Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dora Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dora Ding more than expected).

Fields of papers citing papers by Dora Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dora Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dora Ding. The network helps show where Dora Ding may publish in the future.

Co-authorship network of co-authors of Dora Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Dora Ding. A scholar is included among the top collaborators of Dora Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dora Ding. Dora Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Wang, Jun, Dora Ding, Xiaorong Shao, et al.. (2025). Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis. Diabetes Obesity and Metabolism. 27(8). 4148–4156.
2.
Younis, Islam R., Cara Nelson, Dora Ding, et al.. (2023). Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist. The Journal of Clinical Pharmacology. 63(5). 560–568. 4 indexed citations
3.
Labenz, Christian, Gerrit Toenges, Ming‐Hua Zheng, et al.. (2022). Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. European Journal of Internal Medicine. 98. 53–60. 3 indexed citations
4.
Lawitz, Eric, Bal Raj Bhandari, Peter Ruane, et al.. (2022). Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clinical Gastroenterology and Hepatology. 21(1). 143–152.e3. 34 indexed citations
5.
Sanyal, Arun J., Quentin M. Anstee, Michael Trauner, et al.. (2021). Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 75(5). 1235–1246. 89 indexed citations
6.
Javed, Awais, Georgios Gemenetzis, Vincent P. Groot, et al.. (2020). Presence Of Transitional Circulating Tumor Cells Following Resection Is Associated With Worse Survival In Patients With Delayed Initiation Of Adjuvant Therapy. HPB. 22. S5–S5. 1 indexed citations
7.
8.
Muir, Andrew J., Cynthia Levy, Harry L.A. Janssen, et al.. (2018). Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology. 69(2). 684–698. 144 indexed citations
9.
Bowlus, Christopher L., Krish Patel, Gideon M. Hirschfield, et al.. (2017). Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis. Journal of Hepatology. 66(1). S359–S359. 4 indexed citations
10.
Muir, Andrew J., Zachary Goodman, Christopher L. Bowlus, et al.. (2016). Serum LYSYL Oxidase-Like-2 (SLOXL2) Levels Correlate with Disease Severity in Patients with Primary Sclerosing Cholangitis. Journal of Hepatology. 64(2). S428–S428. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philippe Kolly Breakdown of academic impact, for papers by Hiroaki Hashizume Breakdown of academic impact, for papers by Ashley M. Lakner Breakdown of academic impact, for papers by Jui‐Ting Hu Breakdown of academic impact, for papers by Aurora Giannetti Breakdown of academic impact, for papers by Anna Ludovica Fracanzani Breakdown of academic impact, for papers by Stefanie Haegele Breakdown of academic impact, for papers by Takuya Nagano Breakdown of academic impact, for papers by Emily Zhang Breakdown of academic impact, for papers by Yoshiou Ikeda
Rankless by CCL
2026